Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

A new study describes how monoclonal antibodies raised against SARS-CoV-2 are affected by mutations in the antibody binding site.

20 Aug 2021

SARS-CoV-2 lambda variant escapes immune response via spike mutations

A new study explores the mechanism by which the SARS-CoV-2 lambda variant has acquired immune evasion capabilities above that of the wildtype.

20 Aug 2021

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

A striking new study examines how far antibodies elicited by vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or by natural infection, can neutralize the closely related bat coronavirus (CoV) RaTG13.

19 Aug 2021

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.

19 Aug 2021

Durable highly protective T cell response to AAV-spike vaccine against COVID-19 pneumonia in mice

New research, available as a preprint on the bioRxiv* server, has focused on the role played by T cell immunity, particularly CD8+ cytotoxic T cells, on preventing lethal infection with SARS-CoV-2 in mice infused with peptide-loaded antigen-presenting dendritic cells (DCs).

19 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

Why have COVID-19 caseloads been comparatively low in Africa?

A new study has been published in the International Journal of Environmental Research and Public Health that highlights the potential lessons that the world can draw from Africa on assumptions concerning viral pandemics. This is particularly important, given Africa’s long experience with dangerous infectious diseases.

18 Aug 2021

Study examines prevalence of neutralizing antibodies to HCoV-NL63 in healthy adults in Australia

A new study has been published in the MPDI journal Viruses, which focuses on determining the seroprevalence of neutralizing antibodies against HCoV-NL63, in healthy adults, in a cross-sectional study.

18 Aug 2021

How do glycans affect SARS-CoV-2 spike protein openings?

In a paper recently uploaded to the bioRxiv* preprint server, the role of glycan coating on the SARS-CoV-2 spike protein is further investigated by molecular dynamics simulations of the glycosylated and non-glycosylated protein, identifying several key glycans that play a role in stabilizing and protecting the RBD, and also encourage bonding with the ACE2 receptor.

18 Aug 2021

Increased chemosensory dysfunction with D614G mutation of SARS-CoV-2

A study, available on the pre-print server medRxiv, has determined the underlying molecular mechanisms of how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially the G614 strain, leads to olfactory dysfunction causing anosmia.

18 Aug 2021

Specificity of serological assays against SARS-CoV-2 in patients with parasitic infections

A new study available on the pre-print server medRxiv* aims to assess the specificity of the serological assays of SARS-CoV-2 antibodies among patients known to have a tissue-borne parasitic infection or those who reside in areas where the virus is endemic.

18 Aug 2021

P681R spike mutation enhances replication efficiency of SARS-CoV-2 delta variant

A team of scientists from the University of Texas, USA, has recently revealed that the P681R spike mutation is responsible for increased infectivity of the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The P681R spike mutation increases the replication of the delta variant by increasing the dissociation of S1 and S2 subunits at the furin cleavage site. The study is currently available on the bioRxiv* preprint server.

18 Aug 2021

How delta and kappa variants of SARS-CoV-2 evade the immune system

A new study, available on the bioRxiv* preprint server, describes the neutralizing ability of the monoclonal antibodies against the variants and the difference of the ACE2 binding affinity found in the variants.

17 Aug 2021

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Now, a new study posted to the bioRxiv* preprint server focuses on functional immune memory to SARS-CoV-2, up to nine months in a Southeast Asian cohort, in the absence of re-infection.

16 Aug 2021

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, which has claimed more than 4.3 million lives worldwide. Even after implementing various measures, such as vaccination and social restrictions, SARS-CoV-2 and its variants of concern (VoC) leave the world's public health systems and economies in turmoil.

16 Aug 2021

Tool for defining new SARS-CoV-2 spike nucleotide sequences to Pango lineage sets

In a recent study, a group of researchers determined the degree to which Pango lineages are distinguishable using spike-only nucleotide sequences.

16 Aug 2021

Study reports the prevalence of different types of shock in COVID-19 patients

A new database analysis of critically ill patients with pneumonia related to COVID-19, published in the American Journal of Cardiology and conducted at Hackensack Meridian Hackensack University Medical Center (HUMC), is the first study to report the prevalence of different types of shock in patients with COVID-19.

16 Aug 2021

Angiotensin News and Research

Further Reading

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

SARS-CoV-2 lambda variant escapes immune response via spike mutations

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

Durable highly protective T cell response to AAV-spike vaccine against COVID-19 pneumonia in mice

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

Why have COVID-19 caseloads been comparatively low in Africa?

Study examines prevalence of neutralizing antibodies to HCoV-NL63 in healthy adults in Australia

How do glycans affect SARS-CoV-2 spike protein openings?

Increased chemosensory dysfunction with D614G mutation of SARS-CoV-2

Specificity of serological assays against SARS-CoV-2 in patients with parasitic infections

P681R spike mutation enhances replication efficiency of SARS-CoV-2 delta variant

How delta and kappa variants of SARS-CoV-2 evade the immune system

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Tool for defining new SARS-CoV-2 spike nucleotide sequences to Pango lineage sets

Study reports the prevalence of different types of shock in COVID-19 patients

Research suggests toll-like receptor 4 appears to play role in severe COVID

Role of neutrophil-epithelial interactions in SARS-CoV-2 infection

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News